CG Oncology Statistics
Total Valuation
CG Oncology has a market cap or net worth of $4.77 billion. The enterprise value is $3.67 billion.
| Market Cap | 4.77B |
| Enterprise Value | 3.67B |
Important Dates
The last earnings date was Friday, May 8, 2026, before market open.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CG Oncology has 88.20 million shares outstanding. The number of shares has increased by 13.77% in one year.
| Current Share Class | 88.20M |
| Shares Outstanding | 88.20M |
| Shares Change (YoY) | +13.77% |
| Shares Change (QoQ) | +5.56% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 91.38% |
| Float | 65.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 934.38 |
| Forward PS | 462.06 |
| PB Ratio | 4.33 |
| P/TBV Ratio | 4.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 723.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 31.30, with a Debt / Equity ratio of 0.01.
| Current Ratio | 31.30 |
| Quick Ratio | 30.60 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -20.79% and return on invested capital (ROIC) is -14.89%.
| Return on Equity (ROE) | -20.79% |
| Return on Assets (ROA) | -14.42% |
| Return on Invested Capital (ROIC) | -14.89% |
| Return on Capital Employed (ROCE) | -19.54% |
| Weighted Average Cost of Capital (WACC) | 5.94% |
| Revenue Per Employee | $35,711 |
| Profits Per Employee | -$1.32M |
| Employee Count | 142 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +100.60% in the last 52 weeks. The beta is 0.31, so CG Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +100.60% |
| 50-Day Moving Average | 65.77 |
| 200-Day Moving Average | 50.59 |
| Relative Strength Index (RSI) | 31.10 |
| Average Volume (20 Days) | 953,849 |
Short Selling Information
The latest short interest is 9.18 million, so 10.41% of the outstanding shares have been sold short.
| Short Interest | 9.18M |
| Short Previous Month | 9.22M |
| Short % of Shares Out | 10.41% |
| Short % of Float | 13.95% |
| Short Ratio (days to cover) | 9.78 |
Income Statement
In the last 12 months, CG Oncology had revenue of $5.07 million and -$186.75 million in losses. Loss per share was -$2.35.
| Revenue | 5.07M |
| Gross Profit | -135.44M |
| Operating Income | -214.96M |
| Pretax Income | -186.75M |
| Net Income | -186.75M |
| EBITDA | -212.70M |
| EBIT | -214.96M |
| Loss Per Share | -$2.35 |
Balance Sheet
The company has $1.08 billion in cash and $7.58 million in debt, with a net cash position of $1.07 billion or $12.12 per share.
| Cash & Cash Equivalents | 1.08B |
| Total Debt | 7.58M |
| Net Cash | 1.07B |
| Net Cash Per Share | $12.12 |
| Equity (Book Value) | 1.09B |
| Book Value Per Share | 12.41 |
| Working Capital | 1.07B |
Cash Flow
In the last 12 months, operating cash flow was -$160.01 million and capital expenditures -$422,000, giving a free cash flow of -$160.43 million.
| Operating Cash Flow | -160.01M |
| Capital Expenditures | -422,000 |
| Depreciation & Amortization | 2.26M |
| Net Borrowing | n/a |
| Free Cash Flow | -160.43M |
| FCF Per Share | -$1.82 |
Margins
| Gross Margin | n/a |
| Operating Margin | -4,238.99% |
| Pretax Margin | -3,682.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CG Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.77% |
| Shareholder Yield | -13.77% |
| Earnings Yield | -3.94% |
| FCF Yield | -3.39% |
Analyst Forecast
The average price target for CG Oncology is $90.29, which is 67.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $90.29 |
| Price Target Difference | 67.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 383.93% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CG Oncology has an Altman Z-Score of 41.08 and a Piotroski F-Score of 4.
| Altman Z-Score | 41.08 |
| Piotroski F-Score | 4 |